Highlights of the 2013 Annual Meeting will be discussions on advanced strategies for targeted immunotherapies.

Dedicated sessions on the tumor micro-environment and on combination therapies will talk about disease mechanisms and address the optimization of immunotherapies: Who can benefit, when and why?

Exciting recent results on combining immunotherapies with other standard cancer treatments are presented through preclinical and clinical data. Sessions in therapeutic vaccination, cellular therapy and improving immunity will discuss recent advances and future applications.

In addition, CIP (CIMT Immunoguding Program) and CIMT-RRG (Regulatory Research Group)will hold sessions and panel discussions focusing on standardized and innovative tools for improving the quality of immunomonitoring and facilitating the translation of scientific knowledge to drug development.

Contact: info@kukm.de